International cooperation

University of Hong Kong

Scinosen signed a partnership agreement with the University of Hong Kong in 2021 to collaborate in the field of genetics with Professor Kwan Shin Yuen's team at the Li Ka Shing School of Pharmacy. The two sides plan to establish a "Shenzhen (Hetao) International Genetic Medicine Center" integrating research and medical treatment in Shenzhen, give full play to their respective advantages, especially Shenzhen's advantages in the field of gene medicine and gene therapy segmentation, and promote Shenzhen to become a global leader in this field through cooperation, rather than a catch-up and follower.

The two parties will work closely together to develop new drugs and clinical application technologies for gene therapy. Both sides are confident that the "Gene Medicine Center" will become a highly influential medical center in the field of gene therapy, facing the Guangdong-Hong Kong-Macao Greater Bay Area, through high-level gene medicine and the corresponding clinical application technology research results, export unique tumor gene therapy technology, and build a brand - a new advantage of Shenzhen as a capital of innovation!

The collaboration will focus on genetics, including the following:

1. Development of gene therapy technology for chronic diseases including cancer and diabetes;

2. Development of viral vector gene new drugs, preparation of corresponding viral vectors, construction of gene drugs, preparation of clinical trial samples, etc.;

3. Research on the clinical application technology of Jinyuseng therapy for type II diabetes based on p53 gene, and the corresponding mechanism of action;

4. Development of clinical synergistic application technology of gene therapy, immune cell therapy and targeted therapy, and research on corresponding synergistic mechanism;

5. Customized research, technology transformation and customized production of viral vector gene drugs.